Comparative Effectiveness of a Peer-led O2 Infoline for Patients and Caregivers
Comparative Effectiveness of a Peer-led O2 Infoline for Patients and Caregivers
About 1 million individuals in the US have a prescription for supplemental oxygen (O2). Using
 O2 can prolong life and increase quality of life. Patients often do not use their oxygen as
 prescribed, which means that they are not benefiting as much as they could be from this
 therapy. The purpose of this study is to evaluate whether a PEer-Led O2 Infoline for patients
 and CAregivers (PELICAN) will increase adherence to supplemental oxygen prescription and
 improve health in patients with chronic obstructive pulmonary disease (COPD).
The COPD Foundation operates a peer-led telephone-based information line, but its
 effectiveness in promoting adherence to O2 therapy and patient-centered outcomes is unknown.
 Our overall hypothesis is that a patient-centered Peer-Led O2 InfoLine for patients and
 CAregivers (PELICAN) will increase adherence and improve health. We have developed a
 broad-based collaboration with patients/caregivers, advocacy groups, a national O2 supplier,
 and others to conduct a 3-arm pragmatic clinical trial, to evaluate the comparative
 effectiveness of proactive vs. reactive PELICAN interventions vs. usual care on adherence to
 O2 (primary outcome) and on other patient-centered outcomes (secondary outcomes).
Inclusion Criteria:

 1. Age 18 years or older.

 2. Physician diagnosis of COPD

 3. Physician prescription for home O2 for 24hrs/day, 7 days/week

 4. Willing to use home O2.

 5. Working telephone number.

 Exclusion Criteria:

 1. Unable to read and speak English.

 2. Discharge to home hospice or expected survival less than 6 months.